Cukrzyca typu 2 – redukcja zdarzeń sercowo-naczyniowych przy stosowaniu leku z grupy analogów GLP-1: badanie LEADER

LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med online

The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority)

NEJM, 13 czerwca 2016